Alzheimer's Society comments on the FDA's decision to approve aducanumab
The FDA have announced that they have approved aducanumab for use in early Alzheimer's disease in the US.
Dr Richard Oakley, Head of Research at Alzheimer’s Society, said:
'It’s promising to see that aducanumab has been approved for use in people with early stage Alzheimer’s disease - the first drug to be approved in nearly twenty years by the US regulatory authorities.
'We await the opinion of the European Medicines Agency and the outcome of any application made to the UK regulatory authorities, to give clarity to people with early Alzheimer’s disease in the UK. Whatever the outcome of their decision, this is just the beginning of the road to new treatments for Alzheimer’s disease.
As this drug will only benefit a proportion of people in the early stages of Alzheimer’s disease, there are hundreds of thousands more who may not be eligible, so we must keep searching for drugs for all stages of Alzheimer’s disease and for other types of dementia.
'We are proud to say that Alzheimer’s Society was part of a pivotal genetic discovery for the first Alzheimer’s gene in the 1990s, which paved the way for anti-amyloid drugs like the one announced by Biogen.
'Research will beat dementia. We have seen tremendous progress over the last decade, leading up to this decision today, but we need to maintain the momentum: the Government must honour their commitment to double dementia research funding.
'Dementia is the biggest killer in the UK, so we owe it to all 850,000 people living with dementia in the UK and their families to make a world without dementia a reality.'
What is Aducanumab and what could this dementia drug mean for people with Alzheimer's disease?
The FDA has approved the dementia drug Aducanumab for clinical use for people living with Alzheimer's disease in the USA. Find out more about the drug, its path to approval, and what it means for people with dementia in the UK.